Stock GALD GALDERMA GROUP AG
Add to a list
To use this feature you must be a member
Log inSign up

Galderma Group AG

Equities

GALD

CH1335392721

Personal Products

Market Closed - Swiss Exchange
Other stock markets
 11:31:19 2024-12-13 am EST 		5-day change 1st Jan Change
90.27 CHF +0.07% Intraday chart for Galderma Group AG +2.85% 0.00%
Dec. 13 Galderma Receives U.S. FDA Approval for Nemluvio for Patients with Moderate-to-Severe Atopic Dermatitis CI
Dec. 13 Galderma's Skin Disease Drug Nemolizumab Backed for EU Approval MT
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In

Latest news about Galderma Group AG

Galderma Receives U.S. FDA Approval for Nemluvio for Patients with Moderate-to-Severe Atopic Dermatitis Dec. 13 CI
Galderma's Skin Disease Drug Nemolizumab Backed for EU Approval Dec. 13 MT
CHMP Recommends Approval of Galderma's Nemolizumab for Moderate-To-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union Dec. 13 CI
Global markets live: Nvidia, Snowflake, Reddit, Target, Comcast... Nov. 21Our Logo
Several major shareholders, including EQT, sell shares in Galderma Nov. 21 FW
Galderma's Shareholders to Offload Minority Stake in Upsized Offering Nov. 20 MT
L'Oréal Prices EUR1.25 Billion Bond Offering Oct. 30 MT
L'Oréal: bond placement for 1.25 billion euros Oct. 30 CF
Musk on top of Wall Street Oct. 25Our Logo
Busy Earnings Day Boosts Swiss Stocks Oct. 24 MT
Galderma Group AG, Q3 2024 Sales/ Trading Statement Call, Oct 24, 2024 Oct. 24
Galderma posts 9.2% sales growth in first nine months of 2024 Oct. 24 RE
Galderma Posts Higher Nine-month Net Sales, Narrows FY24 Sales Guidance Oct. 24 MT
Galderma Group AG Revises Earnings Guidance for the Year 2024 Oct. 24 CI
Galderma Announces New Phase III Data from the READY-4 Clinical Trial Oct. 21 CI
IPO: The best and worst IPOs of 2024 Oct. 15Our Logo
IPOs stage fall comeback in Europe Oct. 10 RE
Certain Shares of Galderma Group AG are subject to a Lock-Up Agreement Ending on 30-SEP-2024. Sep. 29 CI
RBC Capital Lifts Price Target on Galderma Group, Maintains Outperform Recommendation Sep. 24 MT
Swiss Stocks Kick Off Rate Decision Week in Green Sep. 23 MT
Galderma Group AG(SWX:GALD) added to S&P Global BMI Index Sep. 22 CI
Galderma Group AG(SWX:GALD) added to FTSE All-World Index Sep. 22 CI
Such a long wait Sep. 05Our Logo
Galderma Stock Falls After Report That Backers Plan to Sell Shares -- Update Sep. 04 DJ
Galderma Stock Falls After Report That Backers Plan to Sell Shares Sep. 04 DJ

Chart Galderma Group AG

Chart Galderma Group AG
GALD: Dynamic Chart

Company Profile

Logo Galderma Group AG
Galderma Group AG is a Switzerland based holding Company, specializing in dermatological treatments and skin care products. The Company, throw its subsidiaries, operates a portfolio of carious self-care brands focusing primarily on dermatological solutions, through its subsidiaries. production within the portfolio include neuromodulators, fillers. and biostimulators. these products are designed to relax winkles via injection, fill wrinkles in a specific location via injection and stimulate the body's cells to function optimally. The production process, for the various products primarily takes place in house, form research and development to manufacturing. In addition, including education, scientific engagements, and other services are offered.
Employees
6,545
Sector
Personal Products
Calendar
2025-01-08 - Baader Swiss Equities Conference
More about the company

Income Statement and Estimates

income-statement-evolution-chart GALDERMA-GROUP-AG More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
101.05USD
Average target price
108.65USD
Spread / Average Target
+7.52%
Consensus
Profit revisions
estimates-change-chart GALDERMA-GROUP-AG Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart GALDERMA-GROUP-AG Company calendar
  1. Stock Market
  2. Equities
  3. GALD Stock
  4. News Galderma Group AG
  5. L'Oréal Prices EUR1.25 Billion Bond Offering